{"id":4819,"date":"2024-12-24T15:08:57","date_gmt":"2024-12-24T09:38:57","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4819"},"modified":"2024-12-24T15:13:57","modified_gmt":"2024-12-24T09:43:57","slug":"global-parkinsons-therapeutic-market-outlook","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook","title":{"rendered":"Parkinson\u2019s Disease Therapeutic Market Trends and Future Prospects"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0938298c08b\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0938298c08b\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook\/#Parkinsons_Disease_Market_Overview\" >Parkinson\u2019s Disease Market Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook\/#Parkinsons_Disease_Therapeutic_Segmentation\" >Parkinson&#8217;s Disease Therapeutic Segmentation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook\/#Regional_Market_Insights_of_Parkinsons_Disease\" >Regional Market Insights of Parkinson&#8217;s Disease\u00a0<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook\/#Parkinsons_Disease_Key_Players_and_Competitive_Landscape\" >Parkinson\u2019s Disease Key Players and Competitive Landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook\/#Parkinsons_Disease_Market_Outlook\" >Parkinson&#8217;s Disease Market Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook\/#Future_Predictions\" >Future Predictions<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong>Parkinson&#8217;s disease<\/strong> is a progressive neurological disorder that affects movement control. It occurs when dopamine-producing neurons in the brain are damaged or die. The exact cause of Parkinson&#8217;s disease is still unknown, but symptoms include <strong><em>tremors, stiffness, and difficulty with coordination.<\/em><\/strong> Parkinson&#8217;s disease progresses through various stages, with symptoms worsening over time, affecting an individual&#8217;s quality of life. Early diagnosis and treatment are key to managing Parkinson&#8217;s and slowing its progression.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\"><strong><em>Parkinson&#8217;s disease therapeutic market<\/em><\/strong><\/a><strong><em> <\/em><\/strong>plays a crucial role in managing the symptoms and progression of the condition. With no cure currently available, the Parkinson&#8217;s disease market focuses on providing treatments that help alleviate symptoms, improve quality of life, and slow disease progression. Medications, such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/dopaminergic-agonist-pipeline-insight\"><strong>dopaminergic therapies<\/strong><\/a><strong>, and advanced treatments like deep brain stimulation, <\/strong>are essential components of the Parkinson&#8217;s disease therapeutic market. As the prevalence of Parkinson&#8217;s continues to rise, advancements in research and drug development are vital to expanding treatment options, offering hope to patients and caregivers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-parkinson-s-disease-market-overview\"><span class=\"ez-toc-section\" id=\"Parkinsons_Disease_Market_Overview\"><\/span>Parkinson\u2019s Disease Market Overview<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <strong>Parkinson&#8217;s disease market<\/strong> is experiencing substantial growth, driven by aging populations and heightened disease awareness. In 2023, the <strong>US market size<\/strong> for <strong>Parkinson&#8217;s disease treatment<\/strong> reached <strong>USD 1.8 billion<\/strong>. With the anticipated launch of novel <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\"><strong>Parkinson&#8217;s disease drugs<\/strong><\/a> such as <strong>SPN-830, Tavapadon, P2B001, and ND0612, <\/strong>alongside advancements in diagnostics and care, the market is poised for significant expansion during the forecast period which is from<strong> 2024 to 2034.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" width=\"1024\" height=\"503\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120933\/Parkinsons-Disease-Market-Insights-2023-1024x503.png\" alt=\"\" class=\"wp-image-30640\" style=\"width:840px;height:auto\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120933\/Parkinsons-Disease-Market-Insights-2023-1024x503.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120933\/Parkinsons-Disease-Market-Insights-2023-300x147.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120933\/Parkinsons-Disease-Market-Insights-2023-150x74.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120933\/Parkinsons-Disease-Market-Insights-2023-768x377.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120933\/Parkinsons-Disease-Market-Insights-2023-1536x754.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120933\/Parkinsons-Disease-Market-Insights-2023-2048x1005.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-parkinson-s-disease-therapeutic-segmentation\"><span class=\"ez-toc-section\" id=\"Parkinsons_Disease_Therapeutic_Segmentation\"><\/span>Parkinson&#8217;s Disease Therapeutic Segmentation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <strong>Parkinson&#8217;s disease treatment landscape<\/strong> is evolving to address unmet needs. Current therapeutic approaches include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Therapy<\/strong>:<br>The mainstay of treatment is <strong>carbidopa\/levodopa<\/strong>, with innovative formulations like <strong>CREXONT, RYTARY, <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/xadago-safinamide-drug-insight-market-forecast\"><strong>XADAGO\/EQUFINA<\/strong><\/a><strong>, and DUOPA<\/strong> enhancing symptom control. Dopamine agonists, MAO-B inhibitors, and transdermal options like <strong>HARUROPI TAPE<\/strong> provide additional avenues for symptom management.<\/li>\n\n\n\n<li><strong>Advanced Therapies<\/strong>:<br>Techniques like deep brain stimulation (DBS) and infusion therapies, such as <strong>levodopa\/carbidopa enteral suspension<\/strong>, are offering advanced solutions for patients with severe motor symptoms.<\/li>\n\n\n\n<li><strong>Emerging Treatment Approaches<\/strong>:<br>Promising drugs targeting a-synuclein pathology, gene therapies, and stem cell-based regenerative strategies signal the arrival of potential <strong>disease-modifying Parkinson&#8217;s disease therapies<\/strong>. Late-stage candidates such as ND0612 and SPN-830 could reshape the <strong>Parkinson&#8217;s disease drug market<\/strong>.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regional-market-insights-of-parkinson-s-disease\"><span class=\"ez-toc-section\" id=\"Regional_Market_Insights_of_Parkinsons_Disease\"><\/span>Regional Market Insights of Parkinson&#8217;s Disease\u00a0<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <strong>Parkinson&#8217;s disease market<\/strong> exhibits regional variability in revenue and growth potential:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>United States<\/strong>: The largest market, valued at ~USD 2 billion in 2023, is expected to grow significantly with increasing awareness and therapeutic advancements.<\/li>\n\n\n\n<li><strong>EU4 and the UK<\/strong>: Germany dominated this region, contributing ~USD 400 million, followed by France and the UK. The EU4 and the UK collectively accounted for 31% of the total market revenue in 2023, with projected growth through 2034.<\/li>\n\n\n\n<li><strong>Japan<\/strong>: The <strong>Parkinson&#8217;s disease treatment market<\/strong> in Japan stood at USD 348 million in 2023 and is expected to expand further during the forecast period.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-parkinson-s-disease-key-players-and-competitive-landscape\"><span class=\"ez-toc-section\" id=\"Parkinsons_Disease_Key_Players_and_Competitive_Landscape\"><\/span>Parkinson\u2019s Disease Key Players and Competitive Landscape<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Parkinson&#8217;s disease market is highly competitive, with a mix of established pharmaceutical companies and emerging biotech firms driving innovation in therapies and treatments. Key players include <strong>Amneal Pharmaceuticals, AbbVie, Newron Pharmaceuticals, Supernus Pharmaceuticals, Inc., Britannia Pharmaceuticals, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), UCB Biopharma SRL, Novartis, Annovis Bio, Cerevel Therapeutics, LLC<\/strong>, and many others.<\/p>\n\n\n\n<p><strong>AbbVie<\/strong> remains a frontrunner in the market, introducing groundbreaking therapies such as Tavapadon, a promising oral dopamine D1\/D5 receptor partial agonist, and DUOPA, a <strong>carbidopa\/levodopa enteral suspension<\/strong> providing advanced options for patients with severe disease progression. AbbVie\u2019s innovative pipeline highlights its commitment to addressing unmet needs in <strong>Parkinson&#8217;s disease treatment<\/strong>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/Emerging-Therapies-for-Parkinsons-Disease-1024x613.png\" alt=\"\" class=\"wp-image-30654\"\/><\/figure>\n\n\n\n<p><strong>Supernus Pharmaceuticals, Inc.<\/strong> and <strong>Britannia Pharmaceuticals<\/strong> are spearheading advancements with late-stage candidates like SPN-830, an apomorphine infusion pump designed to deliver continuous dopaminergic stimulation, reducing &#8220;off&#8221; episodes for patients requiring consistent symptom management.<\/p>\n\n\n\n<p><strong>Pharma Two B<\/strong> is making strides with P2B001, a novel combination therapy that integrates extended-release pramipexole and rasagiline to optimize motor symptom control while minimizing side effects. Similarly, <strong>Mitsubishi Tanabe Pharma (NeuroDerm)<\/strong> is advancing ND0612, a <strong>levodopa\/carbidopa infusion therapy<\/strong>, offering potential breakthroughs in continuous motor symptom management.<\/p>\n\n\n\n<p>Emerging players like <strong>UCB Biopharma SRL, Novartis, Annovis Bio,<\/strong> and <strong>Cerevel Therapeutics, LLC<\/strong> are focusing on innovative therapies targeting underlying disease mechanisms, such as a-synuclein aggregation and neuroregeneration. These efforts, along with advancements in gene therapies and regenerative medicine, contribute to a robust pipeline of potential <strong>Parkinson&#8217;s disease drugs<\/strong>, positioning the market for transformative breakthroughs in the near future.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-parkinson-s-disease-market-outlook\"><span class=\"ez-toc-section\" id=\"Parkinsons_Disease_Market_Outlook\"><\/span>Parkinson&#8217;s Disease Market Outlook<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The future of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\"><strong>Parkinson&#8217;s disease market<\/strong><\/a> lies in the development of innovative treatments that extend beyond symptom management to address the underlying causes of the disease. By targeting mechanisms such as <strong>alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation, pharmaceutical companies <\/strong>have the potential to create therapies capable of slowing or halting neurodegeneration. These efforts are supported by advancements in drug delivery systems, including brain-penetrant small molecules and gene therapies, which aim to enhance precision and efficacy in treatment.<\/p>\n\n\n\n<p>Additionally, the use of biomarkers for early detection and patient stratification is expected to revolutionize how Parkinson\u2019s disease is diagnosed and treated. By identifying patients earlier and tailoring therapies to their specific needs, companies can develop disease-modifying treatments that significantly improve outcomes and establish new standards of care in Parkinson\u2019s disease management.<\/p>\n\n\n\n<p>Recent developments highlight the progress in addressing unmet needs. In<strong> November 2024, Sunbird Bio<\/strong> announced its diagnostic technology, which demonstrated <strong>86% accuracy<\/strong> in classifying blood samples from Parkinson\u2019s disease-positive patients by detecting aggregated alpha-synuclein proteins. This innovation represents a significant step forward in early and accurate diagnosis, a critical area in Parkinson\u2019s care.<\/p>\n\n\n\n<p>Similarly, <strong>AbbVie<\/strong> achieved a major milestone in <strong>October 2024 <\/strong>with FDA approval of <strong>VYALEV (foscarbidopa\/foslevodopa)<\/strong>, the first <strong>24-hour<\/strong> continuous subcutaneous infusion of a levodopa-based therapy. This groundbreaking treatment offers improved management of motor fluctuations in adults with advanced Parkinson&#8217;s disease, addressing a significant challenge in symptom control.<\/p>\n\n\n\n<p>Emerging therapies are also shaping the future landscape. <strong>Supernus Pharmaceuticals<\/strong> and <strong>Britannia Pharmaceuticals<\/strong> have developed <strong>SPN-830<\/strong>, an investigational apomorphine infusion device designed to provide continuous treatment for motor fluctuations (OFF episodes). Offering a less invasive and more convenient administration than existing therapies, SPN-830 has the potential to enhance patient compliance. Following a complete response letter from the FDA in April 2024, Supernus resubmitted its NDA in August 2024, signaling continued progress toward approval.<\/p>\n\n\n\n<p><strong>AbbVie<\/strong>, following its acquisition of <strong>Cerevel Therapeutics<\/strong>, is advancing <strong>Tavapadon<\/strong>, a once-daily oral therapy designed to selectively target dopamine D1\/D5 receptor subtypes. This therapy aims to provide meaningful motor benefits while minimizing side effects such as dyskinesia and impulse control issues. Tavapadon\u2019s Phase III TEMPO-3 trial reported positive results in April 2024, solidifying its potential as a treatment for both early- and late-stage Parkinson\u2019s disease.<\/p>\n\n\n\n<p>Another promising therapy, <strong>P2B001<\/strong>, developed by <strong>Pharma Two B<\/strong>, combines extended-release pramipexole and rasagiline in a once-daily formulation. This dual mechanism aims to optimize motor symptom control while minimizing side effects, offering a potentially superior alternative to current combination therapies. Phase III study results published in November 2023 highlighted its tolerability and efficacy, with an NDA submission to the FDA in progress.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-predictions\"><span class=\"ez-toc-section\" id=\"Future_Predictions\"><\/span>Future Predictions<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Parkinson\u2019s disease market is projected to experience significant growth during the forecast period (2024\u20132034), driven by these therapeutic advancements, increasing disease awareness, and improvements in diagnostic technologies. Late-stage pipeline drugs such as <strong>SPN-830, Tavapadon, and P2B001,<\/strong> alongside innovations like Sunbird Bio\u2019s diagnostic technology, are expected to redefine how Parkinson\u2019s disease is managed. <\/p>\n\n\n\n<p>These developments position the market for transformative breakthroughs, with pharmaceutical companies focusing on curative and disease-modifying therapies that could significantly impact patient care and market dynamics.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-1024x194.png\" alt=\"\" class=\"wp-image-30639\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/02\/23120622\/Parkinsons-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Parkinson&#8217;s disease is a progressive neurological disorder that affects movement control. It occurs when dopamine-producing neurons in the brain are damaged or die. The exact cause of Parkinson&#8217;s disease is still unknown, but symptoms include tremors, stiffness, and difficulty with coordination. Parkinson&#8217;s disease progresses through various stages, with symptoms worsening over time, affecting an individual&#8217;s [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30663,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[450,1826,3422],"industry":[17225],"therapeutic_areas":[17229],"class_list":["post-4819","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-parkinsons","tag-parkinsons-disease","tag-parkinsons-disease-therapeutic-market","industry-pharmaceutical","therapeutic_areas-central-nervous-system"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Parkinson&#039;s Disease: Advances in Treatment &amp; Diagnostics<\/title>\n<meta name=\"description\" content=\"Explore growth in Parkinson&#039;s disease treatments, emerging diagnostics, and therapies like SPN-830 and Tavapadon, shaping the future of care.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Parkinson&#039;s Disease: Advances in Treatment &amp; Diagnostics\" \/>\n<meta property=\"og:description\" content=\"Explore growth in Parkinson&#039;s disease treatments, emerging diagnostics, and therapies like SPN-830 and Tavapadon, shaping the future of care.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-24T09:38:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-24T09:43:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/24150839\/Parkinsons-Disease-Therapeutic-Market-Trends-and-Future-Prospects.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Parkinson's Disease: Advances in Treatment & Diagnostics","description":"Explore growth in Parkinson's disease treatments, emerging diagnostics, and therapies like SPN-830 and Tavapadon, shaping the future of care.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook","og_locale":"en_US","og_type":"article","og_title":"Parkinson's Disease: Advances in Treatment & Diagnostics","og_description":"Explore growth in Parkinson's disease treatments, emerging diagnostics, and therapies like SPN-830 and Tavapadon, shaping the future of care.","og_url":"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-12-24T09:38:57+00:00","article_modified_time":"2024-12-24T09:43:57+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/24150839\/Parkinsons-Disease-Therapeutic-Market-Trends-and-Future-Prospects.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook","url":"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook","name":"Parkinson's Disease: Advances in Treatment & Diagnostics","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/24150839\/Parkinsons-Disease-Therapeutic-Market-Trends-and-Future-Prospects.png","datePublished":"2024-12-24T09:38:57+00:00","dateModified":"2024-12-24T09:43:57+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Explore growth in Parkinson's disease treatments, emerging diagnostics, and therapies like SPN-830 and Tavapadon, shaping the future of care.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/global-parkinsons-therapeutic-market-outlook#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/24150839\/Parkinsons-Disease-Therapeutic-Market-Trends-and-Future-Prospects.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/24150839\/Parkinsons-Disease-Therapeutic-Market-Trends-and-Future-Prospects.png","width":466,"height":284,"caption":"Parkinson\u2019s Disease Therapeutic Market Trends and Future Prospects"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/24150839\/Parkinsons-Disease-Therapeutic-Market-Trends-and-Future-Prospects-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapeutic market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Parkinson\u2019s<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapeutic market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Dec 24, 2024","modified":"Updated on Dec 24, 2024"},"absolute_dates_time":{"created":"Posted on Dec 24, 2024 3:08 pm","modified":"Updated on Dec 24, 2024 3:13 pm"},"featured_img_caption":"Parkinson\u2019s Disease Therapeutic Market Trends and Future Prospects\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4819"}],"version-history":[{"count":5,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4819\/revisions"}],"predecessor-version":[{"id":30667,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4819\/revisions\/30667"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30663"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4819"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4819"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4819"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4819"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}